{"protocolSection":{"identificationModule":{"nctId":"NCT05649137","orgStudyIdInfo":{"id":"NN9536-7545"},"secondaryIdInfos":[{"id":"2022-002235-60","type":"EUDRACT_NUMBER"},{"id":"U1111-1279-0359","type":"OTHER","domain":"World Health Organization (WHO)"}],"organization":{"fullName":"Novo Nordisk A/S","class":"INDUSTRY"},"briefTitle":"A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight","officialTitle":"Effect and Safety of Semaglutide 7.2 mg Once-weekly in Participants With Obesity and Type 2 Diabetes"},"statusModule":{"statusVerifiedDate":"2026-04","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2023-01-04","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2024-10-28","type":"ACTUAL"},"completionDateStruct":{"date":"2024-12-13","type":"ACTUAL"},"studyFirstSubmitDate":"2022-12-05","studyFirstSubmitQcDate":"2022-12-05","studyFirstPostDateStruct":{"date":"2022-12-13","type":"ACTUAL"},"resultsFirstSubmitDate":"2026-03-26","resultsFirstSubmitQcDate":"2026-04-24","resultsFirstPostDateStruct":{"date":"2026-04-27","type":"ACTUAL"},"dispFirstSubmitDate":"2025-10-20","dispFirstPostDateStruct":{"date":"2026-04-27","type":"ACTUAL"},"lastUpdateSubmitDate":"2026-04-24","lastUpdatePostDateStruct":{"date":"2026-04-27","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Novo Nordisk A/S","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This study will look at how much weight participants will lose and how much blood sugar control they achieve from the start to the end of the study. The weight loss in participants taking the investigational high dose of semaglutide will be compared to the weight loss in people taking \"dummy\" medicine and a lower dose of semaglutide. In addition to taking the medicine, participants will have talks with study staff about healthy food choices and how to be more physically active. Participants will either get semaglutide or \"dummy\" medicine. Which treatment participants get is decided by chance. Participants are more likely (4 out of 5) to get semaglutide than the \"dummy\" medicine. The study medicine will be injected briefly, under skin, with a thin needle, typically in the stomach, thighs, or upper arms. After receiving first dose, the dose of semaglutide will be gradually increased until reaching the target dose. The study will last for about 1.5 years"},"conditionsModule":{"conditions":["Obesity","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":512,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Semaglutide 7.2 mg","type":"EXPERIMENTAL","description":"Participants will receive once-weekly injection of semaglutide subcutaneously (s.c.) in 20 week dose escalation period with dose escalation (0.25 milligram \\[mg\\], 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg, and 7.2 mg) every fourth week. Treatment will be continued on the maintenance dose of 7.2 mg once-weekly for an additional 52 weeks until week 72.","interventionNames":["Drug: Semaglutide"]},{"label":"Semaglutide 2.4 mg","type":"EXPERIMENTAL","description":"Participants will receive once-weekly s.c. injection of semaglutide in 20 week dose escalation period with dose escalation (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg) every fourth week until maintenance dose of 2.4 mg of semaglutide was reached. Treatment will be continued on the maintenance dose of 2.4 mg once-weekly for an additional 52 weeks until week 72.","interventionNames":["Drug: Semaglutide"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","description":"Participants will receive once-weekly s.c. injection of placebo matched to semaglutide for 72 weeks.","interventionNames":["Drug: Placebo"]}],"interventions":[{"type":"DRUG","name":"Semaglutide","description":"Participants will receive once-weekly s.c. injections of semaglutide in escalating doses (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg and 7.2 mg) every fourth week. Treatment will be continued on the maintenance dose of 7.2 mg once-weekly for an additional 52 weeks. Injections may be administered in the thigh, abdomen, or upper arm, at any time of day irrespective of meals.","armGroupLabels":["Semaglutide 7.2 mg"]},{"type":"DRUG","name":"Semaglutide","description":"Participants will receive once-weekly s.c. injections of semaglutide in escalating doses (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg) every fourth week. Treatment will be continued on the maintenance dose of 2.4 mg once-weekly for an additional 52 weeks. Injections may be administered in the thigh, abdomen, or upper arm, at any time of day irrespective of meals.","armGroupLabels":["Semaglutide 2.4 mg"]},{"type":"DRUG","name":"Placebo","description":"Participants will receive once-weekly s.c. injection of placebo matched to semaglutide for 72 weeks. Injections may be administered in the thigh, abdomen, or upper arm, at any time of day irrespective of meals.","armGroupLabels":["Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Relative Change in Body Weight","description":"Relative change in body weight from baseline (week 0) to end of treatment (week 72) is presented.","timeFrame":"Baseline (week 0), End of treatment (week 72)"},{"measure":"Number of Participants Who Achieve Body Weight Reduction Greater Than or Equal to (>=) 5% (Yes/no)","description":"Number of participants who achieve body weight reduction \\>=5% is presented. Yes defines participants who achieved body weight reduction \\>= 5% and No defines participants who did not achieve body weight reduction \\>=5%.","timeFrame":"At week 72"}],"secondaryOutcomes":[{"measure":"Number of Participants Who Achieve Body Weight Reduction >= 10% (Yes/no)","description":"Number of participants who achieve body weight reduction \\>=10% is presented. Yes defines participants who achieved body weight reduction greater than or equal to 10% and No defines participants who did not achieve body weight reduction greater than or equal to 10%.","timeFrame":"At week 72"},{"measure":"Number of Participants Who Achieve Body Weight Reduction >= 15% (Yes/no)","description":"Number of participants who achieve body weight reduction \\>=15% is presented. Yes defines participants who achieved body weight reduction greater than or equal to 15% and No defines participants who did not achieve body weight reduction greater than or equal to 15%.","timeFrame":"At week 72"},{"measure":"Number of Participants Who Achieve Body Weight Reduction >= 20% (Yes/no)","description":"Number of participants who achieve body weight reduction \\>=20% is presented. Yes defines participants who achieved body weight reduction greater than or equal to 20% and No defines participants who did not achieve body weight reduction greater than or equal to 20%.","timeFrame":"At week 72"},{"measure":"Change in Waist Circumference","description":"Change in waist circumference from baseline (week 0) to end of treatment (week 72) is presented.","timeFrame":"Baseline (week 0), End of treatment (week 72)"},{"measure":"Change in Glycated Haemoglobin (HbA1c)","description":"Change in HbA1c from baseline (week 0) to end of treatment (week 72) is presented.","timeFrame":"Baseline (week 0), End of treatment (week 72)"},{"measure":"Change in Body Weight","description":"Change in body weight from baseline (week 0) to end of treatment (week 72) is presented.","timeFrame":"Baseline (week 0), End of treatment (week 72)"},{"measure":"Change in Body Mass Index (BMI)","description":"Change in BMI from baseline (week 0) to end of treatment (week 72) is presented.","timeFrame":"Baseline (week 0), End of treatment (week 72)"},{"measure":"Change in Systolic Blood Pressure","description":"Change in systolic blood pressure from baseline (week 0) to end of treatment (week 72) is presented.","timeFrame":"Baseline (week 0), End of treatment (week 72)"},{"measure":"Change in Diastolic Blood Pressure","description":"Change in diastolic blood pressure from baseline (week 0) to end of treatment (week 72) is presented.","timeFrame":"Baseline (week 0), End of treatment (week 72)"},{"measure":"Change in Total Cholesterol (Millimoles Per Liter [mmol/L]) - Ratio to Baseline","description":"Change in total cholesterol in mmol/L from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.","timeFrame":"Baseline (week 0), End of treatment (week 72)"},{"measure":"Change in Total Cholesterol (Milligrams Per Deciliter [mg/dL]) - Ratio to Baseline","description":"Change in total cholesterol in mg/dL from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.","timeFrame":"Baseline (week 0), End of treatment (week 72)"},{"measure":"Change in High-density Lipoprotein (HDL) Cholesterol (mmol/L) - Ratio to Baseline","description":"Change in HDL cholesterol in mmol/L from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.","timeFrame":"Baseline (week 0), End of treatment (week 72)"},{"measure":"Change in HDL Cholesterol (mg/dL) - Ratio to Baseline","description":"Change in HDL cholesterol in mg/dL from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.","timeFrame":"Baseline (week 0), End of treatment (week 72)"},{"measure":"Change in Low-density Lipoprotein (LDL) Cholesterol (mmol/L) - Ratio to Baseline","description":"Change in LDL cholesterol in mmol/L from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.","timeFrame":"Baseline (week 0), End of treatment (week 72)"},{"measure":"Change in LDL Cholesterol (mg/dL) - Ratio to Baseline","description":"Change in LDL cholesterol in mg/dL from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.","timeFrame":"Baseline (week 0), End of treatment (week 72)"},{"measure":"Change in Very-low-density Lipoprotein (VLDL) Cholesterol (mmol/L) - Ratio to Baseline","description":"Change in VLDL cholesterol in mmol/L from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.","timeFrame":"Baseline (week 0), End of treatment (week 72)"},{"measure":"Change in VLDL Cholesterol (mg/dL) - Ratio to Baseline","description":"Change in VLDL cholesterol in mg/dL from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.","timeFrame":"Baseline (week 0), End of treatment (week 72)"},{"measure":"Change in Triglycerides (mmol/L) - Ratio to Baseline","description":"Change in triglycerides in mmol/L from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.","timeFrame":"Baseline (week 0), End of treatment (week 72)"},{"measure":"Change in Triglycerides (mg/dL) - Ratio to Baseline","description":"Change in triglycerides in mg/dL from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.","timeFrame":"Baseline (week 0), End of treatment (week 72)"},{"measure":"Change in Free Fatty Acids (mmol/L) - Ratio to Baseline","description":"Change in free fatty acids in mmol/L from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.","timeFrame":"Baseline (week 0), End of treatment (week 72)"},{"measure":"Change in Free Fatty Acids (mg/dL) - Ratio to Baseline","description":"Change in free fatty acids in mg/dL from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.","timeFrame":"Baseline (week 0), End of treatment (week 72)"},{"measure":"Change in High-sensitivity C-reactive Protein (hsCRP) - Ratio to Baseline","description":"Change in hsCRP in mg/L from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.","timeFrame":"Baseline (week 0), End of treatment (week 72)"},{"measure":"Change in Fasting Plasma Glucose","description":"Change in fasting plasma glucose from baseline (week 0) to end of treatment (week 72) is presented.","timeFrame":"Baseline (week 0), End of treatment (week 72)"},{"measure":"Change in Fasting Serum Insulin (Picomoles Per Liter [Pmol/L]) - Ratio to Baseline","description":"Change in fasting serum insulin in pmol/L from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.","timeFrame":"Baseline (week 0), End of treatment (week 72)"},{"measure":"Change in Fasting Serum Insulin (Milliinternational Units Per Milliliter [mIU/mL]) - Ratio to Baseline","description":"Change in fasting serum insulin in mIU/ml from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.","timeFrame":"Baseline (week 0), End of treatment (week 72)"},{"measure":"Number of Participants With HbA1c Less Than 7.0 % (53 Millimoles Per Mole [mmol/Mol])","description":"Number of participants with HbA1c less than 7.0 % (53 mmol/mol) at week 72 is presented.","timeFrame":"At week 72"},{"measure":"Number of Participants With HbA1c Less Than or Equal to 6.5% (48 mmol/Mol)","description":"Number of participants with HbA1c less than or equal to 6.5% (48 mmol/mol) at week 72 is presented.","timeFrame":"At week 72"},{"measure":"Semaglutide 7.2 mg Versus Placebo: Number of Adverse Events (AEs)","description":"Number of AEs is reported. An AE is any untoward medical occurrence in a clinical study participant that is temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to the IMP.","timeFrame":"At week 81"},{"measure":"Semaglutide 7.2 mg Versus Placebo: Number of Serious Adverse Events (SAEs)","description":"Number of SAEs is reported. A SAE is any untoward medical occurrence that fulfils at least one of the following criteria: results in death, is life threatening, requires inpatient hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or important medical event.","timeFrame":"At week 81"},{"measure":"Change in Pulse","description":"Change in pulse from baseline (week 0) to end of treatment (week 72) is presented.","timeFrame":"Baseline (week 0), End of treatment (week 72)"},{"measure":"Semaglutide 7.2 mg Versus Placebo: Number of Treatment Emergent Severe or Blood Glucose Confirmed Symptomatic Hypoglycaemic Episodes","description":"Number of treatment emergent severe or blood glucose confirmed symptomatic hypoglycaemic episodes is presented.","timeFrame":"At week 81"},{"measure":"Semaglutide 7.2 mg Versus Semaglutide 2.4 mg: Number of AEs","description":"Number of AEs is reported. An AE is any untoward medical occurrence in a clinical study participant that is temporally associated with the use of IMP, whether or not considered related to the IMP.","timeFrame":"At week 81"},{"measure":"Semaglutide 7.2 mg Versus Semaglutide 2.4 mg: Number of SAEs","description":"Number of SAEs is reported. A SAE is any untoward medical occurrence that fulfils at least one of the following criteria: results in death, is life threatening, requires inpatient hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or important medical event.","timeFrame":"At week 81"},{"measure":"Semaglutide 7.2 mg Versus Semaglutide 2.4 mg: Number of Treatment Emergent Severe or Blood Glucose Confirmed Symptomatic Hypoglycaemic Episodes","description":"Number of treatment emergent severe or blood glucose confirmed symptomatic hypoglycaemic episodes is presented.","timeFrame":"At week 81"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female.\n* Age above or equal to 18 years at the time of signing informed consent.\n* BMI greater than or equal to 30.0 kilograms per square meter (kg/m\\^2).\n* Diagnosed with type 2 diabetes (T2D) greater than or equal to 180 days prior to the day of screening.\n* History of at least one self-reported unsuccessful dietary effort to lose body weight.\n* HbA1c 7.0-10.0 percent (53-86 millimoles per mole \\[mmol/mol\\]) (both inclusive) as measured by central laboratory at screening.\n\nExclusion Criteria:\n\n* A self-reported change in body weight greater than 5 kilograms (kg) (11 pounds \\[lbs\\]) within 90 days before screening irrespective of medical records.\n* Personal or first-degree relative(s) history of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma.\n* Renal impairment with estimated Glomerular Filtration Rate (eGFR) less than 30 milliliters per minute per 1.73 square meter (30 mL/min/1.73 m\\^2) (less than 45 mL/min/1.73 m\\^2 in participants treated with Sodium-glucose Cotransporter-2 \\[SGLT2i\\]) according to Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation as defined by Kidney Disease: Improving Global Outcomes (KDIGO) 2012 by the central laboratory at screening.\n* Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within 90 days before screening or in the period between screening and randomization. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Clinical Transparency (dept. 2834)","affiliation":"Novo Nordisk A/S","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Univ of Alabama Birmingham","city":"Birmingham","state":"Alabama","zip":"35222","country":"United States","geoPoint":{"lat":33.52066,"lon":-86.80249}},{"facility":"Chambliss Clinical Trials, LLC","city":"Montgomery","state":"Alabama","zip":"36106","country":"United States","geoPoint":{"lat":32.36681,"lon":-86.29997}},{"facility":"John Muir Physicians Network","city":"Concord","state":"California","zip":"94520","country":"United States","geoPoint":{"lat":37.97798,"lon":-122.03107}},{"facility":"Velocity Clinical Research Westlake","city":"Los Angeles","state":"California","zip":"90057","country":"United States","geoPoint":{"lat":34.05223,"lon":-118.24368}},{"facility":"Diablo Clinical Research, Inc.","city":"Walnut Creek","state":"California","zip":"94598","country":"United States","geoPoint":{"lat":37.90631,"lon":-122.06496}},{"facility":"New West Physicians PC","city":"Golden","state":"Colorado","zip":"80401","country":"United States","geoPoint":{"lat":39.75554,"lon":-105.2211}},{"facility":"ARS- Deland CRU","city":"DeLand","state":"Florida","zip":"32720","country":"United States","geoPoint":{"lat":29.02832,"lon":-81.30312}},{"facility":"Jacksonville Ctr for Clin Res","city":"Jacksonville","state":"Florida","zip":"32216","country":"United States","geoPoint":{"lat":30.33218,"lon":-81.65565}},{"facility":"Florida Inst For Clin Res LLC","city":"Orlando","state":"Florida","zip":"32825","country":"United States","geoPoint":{"lat":28.53834,"lon":-81.37924}},{"facility":"Oviedo Medical Research, LLC","city":"Oviedo","state":"Florida","zip":"32765","country":"United States","geoPoint":{"lat":28.67,"lon":-81.20812}},{"facility":"Hope Clin Res & Wellness","city":"Conyers","state":"Georgia","zip":"30094","country":"United States","geoPoint":{"lat":33.66761,"lon":-84.01769}},{"facility":"AMC Community Endocrinology","city":"Albany","state":"New York","zip":"12203","country":"United States","geoPoint":{"lat":42.65258,"lon":-73.75623}},{"facility":"University of North Carolina","city":"Chapel Hill","state":"North Carolina","zip":"27514","country":"United States","geoPoint":{"lat":35.9132,"lon":-79.05584}},{"facility":"PharmQuest Life Sciences LLC","city":"Greensboro","state":"North Carolina","zip":"27408","country":"United States","geoPoint":{"lat":36.07264,"lon":-79.79198}},{"facility":"Amarillo Med Spec LLP","city":"Amarillo","state":"Texas","zip":"79106","country":"United States","geoPoint":{"lat":35.222,"lon":-101.8313}},{"facility":"Elligo Clin Res Centre","city":"Austin","state":"Texas","zip":"78704","country":"United States","geoPoint":{"lat":30.26715,"lon":-97.74306}},{"facility":"Velocity Clin Res, Dallas","city":"Dallas","state":"Texas","zip":"75230","country":"United States","geoPoint":{"lat":32.78306,"lon":-96.80667}},{"facility":"UT Southwestern Medical Center - Lingvay","city":"Dallas","state":"Texas","zip":"75390","country":"United States","geoPoint":{"lat":32.78306,"lon":-96.80667}},{"facility":"PlanIt Research, PLLC","city":"Houston","state":"Texas","zip":"77079","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"DCOL Ctr for Clin Res","city":"Longview","state":"Texas","zip":"75605","country":"United States","geoPoint":{"lat":32.5007,"lon":-94.74049}},{"facility":"Sugar Lakes Family Practice PA","city":"Sugar Land","state":"Texas","zip":"77479","country":"United States","geoPoint":{"lat":29.61968,"lon":-95.63495}},{"facility":"National Clin Res Inc.","city":"Richmond","state":"Virginia","zip":"23294","country":"United States","geoPoint":{"lat":37.55376,"lon":-77.46026}},{"facility":"Selma Medical Associates","city":"Winchester","state":"Virginia","zip":"22601-3834","country":"United States","geoPoint":{"lat":39.18566,"lon":-78.16333}},{"facility":"MHAT - Blagoevgrad AD, Department of Internal Diseases","city":"Blagoevgrad","zip":"2700","country":"Bulgaria","geoPoint":{"lat":42.01457,"lon":23.09804}},{"facility":"IPSOMC - Dr. Georgi Marinov","city":"Burgas","zip":"8000","country":"Bulgaria","geoPoint":{"lat":42.50651,"lon":27.46886}},{"facility":"Medical Center Viva Feniks OOD","city":"Dobrich","zip":"9300","country":"Bulgaria","geoPoint":{"lat":43.56491,"lon":27.83138}},{"facility":"UMHAT Pulmed OOD - Pazardzhik, Department of Internal Diseases","city":"Pazardzhik","zip":"4400","country":"Bulgaria","geoPoint":{"lat":42.19934,"lon":24.33318}},{"facility":"MHAT Sveta Karidad EAD","city":"Plovdiv","zip":"4004","country":"Bulgaria","geoPoint":{"lat":42.15387,"lon":24.75001}},{"facility":"MHAT Hadzhi Dimitar OOD","city":"Sliven","zip":"8800","country":"Bulgaria","geoPoint":{"lat":42.68607,"lon":26.32558}},{"facility":"DCC VII - Sofia EOOD, Endocrinology","city":"Sofia","zip":"1233","country":"Bulgaria","geoPoint":{"lat":42.69751,"lon":23.32415}},{"facility":"UMHAT Prof. Dr. Stoyan Kirkovich AD","city":"Stara Zagora","zip":"6003","country":"Bulgaria","geoPoint":{"lat":42.43205,"lon":25.64262}},{"facility":"MHAT Sveti Panteleimon - Yambol AD","city":"Yambol","zip":"8600","country":"Bulgaria","geoPoint":{"lat":42.48243,"lon":26.50006}},{"facility":"Ocean West Research Clinic","city":"Surrey","state":"British Columbia","zip":"V3Z 2N6","country":"Canada","geoPoint":{"lat":49.10635,"lon":-122.82509}},{"facility":"G.A. Research Associates Ltd.","city":"Moncton","state":"New Brunswick","zip":"E1G 1A7","country":"Canada","geoPoint":{"lat":46.09454,"lon":-64.7965}},{"facility":"Nova Scotia Hlth Halifax","city":"Halifax","state":"Nova Scotia","zip":"B3H 1V7","country":"Canada","geoPoint":{"lat":44.64269,"lon":-63.57688}},{"facility":"Premier Clinical Trial Research Network (PCTRN)","city":"Hamilton","state":"Ontario","zip":"L8L 5G4","country":"Canada","geoPoint":{"lat":43.25011,"lon":-79.84963}},{"facility":"Wharton Medical Clinic Clinical Trials (Hamilton)","city":"Hamilton","state":"Ontario","zip":"L8L 5G8","country":"Canada","geoPoint":{"lat":43.25011,"lon":-79.84963}},{"facility":"Milestone Research","city":"London","state":"Ontario","zip":"N5W 6A2","country":"Canada","geoPoint":{"lat":42.98339,"lon":-81.23304}},{"facility":"Lausmed Kft.","city":"Baja","state":"Bács-Kiskun county","zip":"6500","country":"Hungary","geoPoint":{"lat":46.18299,"lon":18.95307}},{"facility":"Belinus Bt.","city":"Debrecen","state":"Hajdú-Bihar","zip":"4025","country":"Hungary","geoPoint":{"lat":47.53167,"lon":21.62444}},{"facility":"Borbánya Praxis E.Ü. Kft.","city":"Nyíregyháza","state":"Szabolcs-Szatmar Varmegye","zip":"4405","country":"Hungary","geoPoint":{"lat":47.95539,"lon":21.71671}},{"facility":"ClinDiab Egészségügyi Szolgáltató és Kereskedelmi Kft.","city":"Budapest","zip":"1089","country":"Hungary","geoPoint":{"lat":47.49835,"lon":19.04045}},{"facility":"Bajcsy-Zsilinszky Kórház","city":"Budapest","zip":"1106","country":"Hungary","geoPoint":{"lat":47.49835,"lon":19.04045}},{"facility":"MED-TIMA Kft.","city":"Budapest","zip":"1132","country":"Hungary","geoPoint":{"lat":47.49835,"lon":19.04045}},{"facility":"Fejér Megyei Szent György Oktatókórház","city":"Székesfehérvár","zip":"8000","country":"Hungary","geoPoint":{"lat":47.18995,"lon":18.41034}},{"facility":"Med. Cent. Diabet. Endo. Metabol. DIAB-ENDO-MET","city":"Krakow","state":"Lesser Poland Voivodeship","zip":"31-261","country":"Poland","geoPoint":{"lat":50.06143,"lon":19.93658}},{"facility":"NZOZ Przychodnia Specjalistyczna Medica","city":"Lublin","state":"Lubelski","zip":"20-538","country":"Poland","geoPoint":{"lat":51.25058,"lon":22.57009}},{"facility":"NZOZ \"CenterMed Lublin\" Sp. z o.o.","city":"Lublin","state":"Lublin Voivodeship","zip":"20-044","country":"Poland","geoPoint":{"lat":51.25058,"lon":22.57009}},{"facility":"Kresmed Sp. z o. o.","city":"Bialystok","state":"Podlaskie Voivodeship","zip":"15-481","country":"Poland","geoPoint":{"lat":53.13333,"lon":23.16433}},{"facility":"Centrum Medyczne Pratia Gdynia","city":"Gdynia","state":"Pomeranian Voivodeship","zip":"81-338","country":"Poland","geoPoint":{"lat":54.51889,"lon":18.53188}},{"facility":"Uniwersyteckie Centrum Kliniczne SUM w Katowicach","city":"Katowice","zip":"40-752","country":"Poland","geoPoint":{"lat":50.2597,"lon":19.02173}},{"facility":"NBR Polska Tomasz Klodawski","city":"Warsaw","zip":"00-710","country":"Poland","geoPoint":{"lat":52.22977,"lon":21.01178}},{"facility":"PANSTWOWY INSTYTUT MEDYCZNY MSWiA","city":"Warsaw","zip":"02-507","country":"Poland","geoPoint":{"lat":52.22977,"lon":21.01178}},{"facility":"ULS De Matosinhos E.P.E.- Hospital Pedro Hispano","city":"Senhora Da Hora, Matosinhos","state":"Matosinhos","zip":"4464-513","country":"Portugal"},{"facility":"APDP - Associação Protectora dos Diabéticos de Portugal","city":"Lisbon","zip":"1250-230","country":"Portugal","geoPoint":{"lat":38.72509,"lon":-9.1498}},{"facility":"Unidade Local De Saúde De Lisboa Ocidental E.P.E. - Hospital Egas Moniz","city":"Lisbon","zip":"1349-019","country":"Portugal","geoPoint":{"lat":38.72509,"lon":-9.1498}},{"facility":"Hospital da Luz Lisboa, S.A.","city":"Lisbon","zip":"1500-650","country":"Portugal","geoPoint":{"lat":38.72509,"lon":-9.1498}},{"facility":"ULS De São João, E.P.E. - Hospital de São João","city":"Porto","zip":"4200-319","country":"Portugal","geoPoint":{"lat":41.1485,"lon":-8.61097}},{"facility":"Hospital da Luz Arrabida, S.A.","city":"Vila Nova de Gaia","zip":"4400-346","country":"Portugal","geoPoint":{"lat":41.12401,"lon":-8.61241}},{"facility":"DIADA s.r.o.","city":"Bardejov","zip":"08501","country":"Slovakia","geoPoint":{"lat":49.29175,"lon":21.27271}},{"facility":"DIADA, s.r.o.","city":"Bardejov","zip":"08501","country":"Slovakia","geoPoint":{"lat":49.29175,"lon":21.27271}},{"facility":"Diab - Int, s.r.o.","city":"Bytča","zip":"014 01","country":"Slovakia","geoPoint":{"lat":49.22404,"lon":18.55878}},{"facility":"ENDOMED, s.r.o.","city":"Košice","zip":"04013","country":"Slovakia","geoPoint":{"lat":48.71441,"lon":21.25802}},{"facility":"MED-DIA CENTRUM s.r.o.","city":"Považská Bystrica","zip":"01701","country":"Slovakia","geoPoint":{"lat":49.12153,"lon":18.42169}},{"facility":"DIABETOL, s.r.o.","city":"Prešov","zip":"080 01","country":"Slovakia","geoPoint":{"lat":48.99923,"lon":21.2355}},{"facility":"Phoenix Pharma","city":"Port Elizabeth","state":"Eastern Cape","zip":"6001","country":"South Africa","geoPoint":{"lat":-33.96109,"lon":25.61494}},{"facility":"Medi-Clinic Bloemfontein","city":"Bloemfontein","state":"Free State","zip":"9301","country":"South Africa","geoPoint":{"lat":-29.12107,"lon":26.214}},{"facility":"Soweto Clinical Trial Centre","city":"Johannesburg","state":"Gauteng","zip":"1818","country":"South Africa","geoPoint":{"lat":-26.20227,"lon":28.04363}},{"facility":"Deepak Lakha","city":"Johannesburg","state":"Gauteng","zip":"1820","country":"South Africa","geoPoint":{"lat":-26.20227,"lon":28.04363}},{"facility":"Hemant Makan","city":"Johannesburg","state":"Gauteng","zip":"1827","country":"South Africa","geoPoint":{"lat":-26.20227,"lon":28.04363}},{"facility":"Wits Bara Clinical Trial Site","city":"Johannesburg","state":"Gauteng","zip":"2013","country":"South Africa","geoPoint":{"lat":-26.20227,"lon":28.04363}},{"facility":"Maxwell Centre","city":"Durban","state":"KwaZulu-Natal","zip":"4001","country":"South Africa","geoPoint":{"lat":-29.8579,"lon":31.0292}},{"facility":"Precise Clinical Solutions (Pty) Ltd","city":"Durban","state":"KwaZulu-Natal","zip":"4092","country":"South Africa","geoPoint":{"lat":-29.8579,"lon":31.0292}},{"facility":"Dr N.K. Gounden Medical Centre","city":"Durban","state":"KwaZulu-Natal","zip":"4093","country":"South Africa","geoPoint":{"lat":-29.8579,"lon":31.0292}},{"facility":"Lenmed Shifa Private Hospital","city":"Durban","state":"KwaZulu-Natal","zip":"4901","country":"South Africa","geoPoint":{"lat":-29.8579,"lon":31.0292}},{"facility":"Dr T Padayachee","city":"eMkhomazi","state":"KwaZulu-Natal","zip":"4170","country":"South Africa","geoPoint":{"lat":-30.20672,"lon":30.79641}}]},"referencesModule":{"references":[{"pmid":"40961953","type":"DERIVED","citation":"Lingvay I, Bergenheim SJ, Buse JB, Freitas P, Garvey WT, Harder-Lauridsen NM, Rosenstock J, Sahu K, Wharton S; STEP UP T2D trial group. Once-weekly semaglutide 7.2 mg in adults with obesity and type 2 diabetes (STEP UP T2D): a randomised, controlled, phase 3b trial. Lancet Diabetes Endocrinol. 2025 Nov;13(11):935-948. doi: 10.1016/S2213-8587(25)00225-6. Epub 2025 Sep 14."}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"According to the Novo Nordisk disclosure commitment on novonordisktrials.com","url":"http://novonordisk-trials.com"}},"resultsSection":{"participantFlowModule":{"recruitmentDetails":"The trial was conducted at 68 sites in 8 countries.","groups":[{"id":"FG000","title":"Semaglutide 7.2 mg","description":"Participants received escalated dose of semaglutide subcutaneously (s.c.) (0.25, 0.5, 1.0, 1.7, and 2.4 milligrams \\[mg\\]) once weekly for 20 weeks followed by a maintenance dose of semaglutide 7.2 mg s.c. once weekly for 52 weeks."},{"id":"FG001","title":"Semaglutide 2.4 mg","description":"Participants received escalated dose of semaglutide s.c. (0.25, 0.5, 1.0, 1.7 and 2.4 mg) once weekly for 20 weeks followed by a maintenance dose of semaglutide 2.4 mg s.c. once weekly for 52 weeks."},{"id":"FG002","title":"Placebo","description":"Participants received matching placebo to semaglutide s.c. once a week for 72 weeks."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"307"},{"groupId":"FG001","numSubjects":"103"},{"groupId":"FG002","numSubjects":"102"}]},{"type":"Full Analysis Set","achievements":[{"groupId":"FG000","numSubjects":"307"},{"groupId":"FG001","numSubjects":"103"},{"groupId":"FG002","numSubjects":"102"}]},{"type":"Safety Analysis Set","achievements":[{"groupId":"FG000","numSubjects":"307"},{"groupId":"FG001","numSubjects":"103"},{"groupId":"FG002","numSubjects":"102"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"295"},{"groupId":"FG001","numSubjects":"100"},{"groupId":"FG002","numSubjects":"96"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"12"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"6"}]}],"dropWithdraws":[{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"3"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"2"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"1"}]},{"type":"Unspecified reason","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Full analysis set included all randomised participants.","groups":[{"id":"BG000","title":"Semaglutide 7.2 mg","description":"Participants received escalated dose of semaglutide subcutaneously (s.c.) (0.25, 0.5, 1.0, 1.7, and 2.4 milligrams \\[mg\\]) once weekly for 20 weeks followed by a maintenance dose of semaglutide 7.2 mg s.c. once weekly for 52 weeks."},{"id":"BG001","title":"Semaglutide 2.4 mg","description":"Participants received escalated dose of semaglutide s.c. (0.25, 0.5, 1.0, 1.7 and 2.4 mg) once weekly for 20 weeks followed by a maintenance dose of semaglutide 2.4 mg s.c. once weekly for 52 weeks."},{"id":"BG002","title":"Placebo","description":"Participants received matching placebo to semaglutide s.c. once a week for 72 weeks."},{"id":"BG003","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"307"},{"groupId":"BG001","value":"103"},{"groupId":"BG002","value":"102"},{"groupId":"BG003","value":"512"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"57","spread":"10"},{"groupId":"BG001","value":"58","spread":"10"},{"groupId":"BG002","value":"55","spread":"10"},{"groupId":"BG003","value":"56","spread":"10"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"166"},{"groupId":"BG001","value":"47"},{"groupId":"BG002","value":"52"},{"groupId":"BG003","value":"265"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"141"},{"groupId":"BG001","value":"56"},{"groupId":"BG002","value":"50"},{"groupId":"BG003","value":"247"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"16"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"8"},{"groupId":"BG003","value":"29"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"291"},{"groupId":"BG001","value":"98"},{"groupId":"BG002","value":"94"},{"groupId":"BG003","value":"483"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"19"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"32"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"5"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"22"},{"groupId":"BG001","value":"13"},{"groupId":"BG002","value":"9"},{"groupId":"BG003","value":"44"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"258"},{"groupId":"BG001","value":"83"},{"groupId":"BG002","value":"87"},{"groupId":"BG003","value":"428"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"2"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Relative Change in Body Weight","description":"Relative change in body weight from baseline (week 0) to end of treatment (week 72) is presented.","populationDescription":"Full analysis set included all randomized participants. Overall number of participants analyzed = Participants with available data for the outcome measure.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Percentage (%) change in body weight","timeFrame":"Baseline (week 0), End of treatment (week 72)","groups":[{"id":"OG000","title":"Semaglutide 7.2 mg","description":"Participants received escalated dose of semaglutide subcutaneously (s.c.) (0.25, 0.5, 1.0, 1.7, and 2.4 milligrams \\[mg\\]) once weekly for 20 weeks followed by a maintenance dose of semaglutide 7.2 mg s.c. once weekly for 52 weeks."},{"id":"OG001","title":"Semaglutide 2.4 mg","description":"Participants received escalated dose of semaglutide s.c. (0.25, 0.5, 1.0, 1.7 and 2.4 mg) once weekly for 20 weeks followed by a maintenance dose of semaglutide 2.4 mg s.c. once weekly for 52 weeks."},{"id":"OG002","title":"Placebo","description":"Participants received matching placebo to semaglutide s.c. once a week for 72 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"291"},{"groupId":"OG001","value":"97"},{"groupId":"OG002","value":"95"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.5","spread":"8.7"},{"groupId":"OG001","value":"-10.7","spread":"8.1"},{"groupId":"OG002","value":"-4.0","spread":"6.2"}]}]}],"analyses":[{"groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","statisticalMethod":"ANCOVA","paramType":"Treatment difference","paramValue":"-9.33","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-10.95","ciUpperLimit":"-7.71"}]},{"type":"PRIMARY","title":"Number of Participants Who Achieve Body Weight Reduction Greater Than or Equal to (>=) 5% (Yes/no)","description":"Number of participants who achieve body weight reduction \\>=5% is presented. Yes defines participants who achieved body weight reduction \\>= 5% and No defines participants who did not achieve body weight reduction \\>=5%.","populationDescription":"Full analysis set included all randomized participants. Overall number of participants analyzed = Participants with available data for the outcome measure.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"At week 72","groups":[{"id":"OG000","title":"Semaglutide 7.2 mg","description":"Participants received escalated dose of semaglutide subcutaneously (s.c.) (0.25, 0.5, 1.0, 1.7, and 2.4 milligrams \\[mg\\]) once weekly for 20 weeks followed by a maintenance dose of semaglutide 7.2 mg s.c. once weekly for 52 weeks."},{"id":"OG001","title":"Semaglutide 2.4 mg","description":"Participants received escalated dose of semaglutide s.c. (0.25, 0.5, 1.0, 1.7 and 2.4 mg) once weekly for 20 weeks followed by a maintenance dose of semaglutide 2.4 mg s.c. once weekly for 52 weeks."},{"id":"OG002","title":"Placebo","description":"Participants received matching placebo to semaglutide s.c. once a week for 72 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"291"},{"groupId":"OG001","value":"97"},{"groupId":"OG002","value":"95"}]}],"classes":[{"categories":[{"title":"Yes","measurements":[{"groupId":"OG000","value":"251"},{"groupId":"OG001","value":"73"},{"groupId":"OG002","value":"33"}]},{"title":"No","measurements":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"62"}]}]}],"analyses":[{"groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","statisticalMethod":"Binary regression model","paramType":"Odds Ratio (OR)","paramValue":"10.03","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"5.96","ciUpperLimit":"16.87"}]},{"type":"SECONDARY","title":"Number of Participants Who Achieve Body Weight Reduction >= 10% (Yes/no)","description":"Number of participants who achieve body weight reduction \\>=10% is presented. Yes defines participants who achieved body weight reduction greater than or equal to 10% and No defines participants who did not achieve body weight reduction greater than or equal to 10%.","populationDescription":"Full analysis set included all randomized participants. Overall number of participants analyzed = Participants with available data for the outcome measure","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"At week 72","groups":[{"id":"OG000","title":"Semaglutide 7.2 mg","description":"Participants received escalated dose of semaglutide subcutaneously (s.c.) (0.25, 0.5, 1.0, 1.7, and 2.4 milligrams \\[mg\\]) once weekly for 20 weeks followed by a maintenance dose of semaglutide 7.2 mg s.c. once weekly for 52 weeks."},{"id":"OG001","title":"Semaglutide 2.4 mg","description":"Participants received escalated dose of semaglutide s.c. (0.25, 0.5, 1.0, 1.7 and 2.4 mg) once weekly for 20 weeks followed by a maintenance dose of semaglutide 2.4 mg s.c. once weekly for 52 weeks."},{"id":"OG002","title":"Placebo","description":"Participants received matching placebo to semaglutide s.c. once a week for 72 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"291"},{"groupId":"OG001","value":"97"},{"groupId":"OG002","value":"95"}]}],"classes":[{"categories":[{"title":"Yes","measurements":[{"groupId":"OG000","value":"183"},{"groupId":"OG001","value":"50"},{"groupId":"OG002","value":"11"}]},{"title":"No","measurements":[{"groupId":"OG000","value":"108"},{"groupId":"OG001","value":"47"},{"groupId":"OG002","value":"84"}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Achieve Body Weight Reduction >= 15% (Yes/no)","description":"Number of participants who achieve body weight reduction \\>=15% is presented. Yes defines participants who achieved body weight reduction greater than or equal to 15% and No defines participants who did not achieve body weight reduction greater than or equal to 15%.","populationDescription":"Full analysis set included all randomized participants. Overall number of participants analyzed = Participants with available data for the outcome measure.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"At week 72","groups":[{"id":"OG000","title":"Semaglutide 7.2 mg","description":"Participants received escalated dose of semaglutide subcutaneously (s.c.) (0.25, 0.5, 1.0, 1.7, and 2.4 milligrams \\[mg\\]) once weekly for 20 weeks followed by a maintenance dose of semaglutide 7.2 mg s.c. once weekly for 52 weeks."},{"id":"OG001","title":"Semaglutide 2.4 mg","description":"Participants received escalated dose of semaglutide s.c. (0.25, 0.5, 1.0, 1.7 and 2.4 mg) once weekly for 20 weeks followed by a maintenance dose of semaglutide 2.4 mg s.c. once weekly for 52 weeks."},{"id":"OG002","title":"Placebo","description":"Participants received matching placebo to semaglutide s.c. once a week for 72 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"291"},{"groupId":"OG001","value":"97"},{"groupId":"OG002","value":"95"}]}],"classes":[{"categories":[{"title":"Yes","measurements":[{"groupId":"OG000","value":"120"},{"groupId":"OG001","value":"28"},{"groupId":"OG002","value":"7"}]},{"title":"No","measurements":[{"groupId":"OG000","value":"171"},{"groupId":"OG001","value":"69"},{"groupId":"OG002","value":"88"}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Achieve Body Weight Reduction >= 20% (Yes/no)","description":"Number of participants who achieve body weight reduction \\>=20% is presented. Yes defines participants who achieved body weight reduction greater than or equal to 20% and No defines participants who did not achieve body weight reduction greater than or equal to 20%.","populationDescription":"Full analysis set included all randomized participants. Overall number of participants analyzed = Participants with available data for the outcome measure.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"At week 72","groups":[{"id":"OG000","title":"Semaglutide 7.2 mg","description":"Participants received escalated dose of semaglutide subcutaneously (s.c.) (0.25, 0.5, 1.0, 1.7, and 2.4 milligrams \\[mg\\]) once weekly for 20 weeks followed by a maintenance dose of semaglutide 7.2 mg s.c. once weekly for 52 weeks."},{"id":"OG001","title":"Semaglutide 2.4 mg","description":"Participants received escalated dose of semaglutide s.c. (0.25, 0.5, 1.0, 1.7 and 2.4 mg) once weekly for 20 weeks followed by a maintenance dose of semaglutide 2.4 mg s.c. once weekly for 52 weeks."},{"id":"OG002","title":"Placebo","description":"Participants received matching placebo to semaglutide s.c. once a week for 72 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"291"},{"groupId":"OG001","value":"97"},{"groupId":"OG002","value":"95"}]}],"classes":[{"categories":[{"title":"Yes","measurements":[{"groupId":"OG000","value":"62"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"2"}]},{"title":"No","measurements":[{"groupId":"OG000","value":"229"},{"groupId":"OG001","value":"83"},{"groupId":"OG002","value":"93"}]}]}]},{"type":"SECONDARY","title":"Change in Waist Circumference","description":"Change in waist circumference from baseline (week 0) to end of treatment (week 72) is presented.","populationDescription":"Full analysis set included all randomized participants. Overall number of participants analyzed = Participants with available data for the outcome measure.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Centimeters (cm)","timeFrame":"Baseline (week 0), End of treatment (week 72)","groups":[{"id":"OG000","title":"Semaglutide 7.2 mg","description":"Participants received escalated dose of semaglutide subcutaneously (s.c.) (0.25, 0.5, 1.0, 1.7, and 2.4 milligrams \\[mg\\]) once weekly for 20 weeks followed by a maintenance dose of semaglutide 7.2 mg s.c. once weekly for 52 weeks."},{"id":"OG001","title":"Semaglutide 2.4 mg","description":"Participants received escalated dose of semaglutide s.c. (0.25, 0.5, 1.0, 1.7 and 2.4 mg) once weekly for 20 weeks followed by a maintenance dose of semaglutide 2.4 mg s.c. once weekly for 52 weeks."},{"id":"OG002","title":"Placebo","description":"Participants received matching placebo to semaglutide s.c. once a week for 72 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"291"},{"groupId":"OG001","value":"97"},{"groupId":"OG002","value":"95"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.6","spread":"10.5"},{"groupId":"OG001","value":"-10.6","spread":"8.4"},{"groupId":"OG002","value":"-6.5","spread":"10.6"}]}]}]},{"type":"SECONDARY","title":"Change in Glycated Haemoglobin (HbA1c)","description":"Change in HbA1c from baseline (week 0) to end of treatment (week 72) is presented.","populationDescription":"Full analysis set included all randomized participants. Overall number of participants analyzed = Participants with available data for the outcome measure.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Percentage of HbA1c","timeFrame":"Baseline (week 0), End of treatment (week 72)","groups":[{"id":"OG000","title":"Semaglutide 7.2 mg","description":"Participants received escalated dose of semaglutide subcutaneously (s.c.) (0.25, 0.5, 1.0, 1.7, and 2.4 milligrams \\[mg\\]) once weekly for 20 weeks followed by a maintenance dose of semaglutide 7.2 mg s.c. once weekly for 52 weeks."},{"id":"OG001","title":"Semaglutide 2.4 mg","description":"Participants received escalated dose of semaglutide s.c. (0.25, 0.5, 1.0, 1.7 and 2.4 mg) once weekly for 20 weeks followed by a maintenance dose of semaglutide 2.4 mg s.c. once weekly for 52 weeks."},{"id":"OG002","title":"Placebo","description":"Participants received matching placebo to semaglutide s.c. once a week for 72 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"288"},{"groupId":"OG001","value":"96"},{"groupId":"OG002","value":"94"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.8","spread":"1.2"},{"groupId":"OG001","value":"-1.7","spread":"1.0"},{"groupId":"OG002","value":"-0.3","spread":"1.3"}]}]}]},{"type":"SECONDARY","title":"Change in Body Weight","description":"Change in body weight from baseline (week 0) to end of treatment (week 72) is presented.","populationDescription":"Full analysis set included all randomized participants. Overall number of participants analyzed = Participants with available data for the outcome measure.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Kilograms (kg)","timeFrame":"Baseline (week 0), End of treatment (week 72)","groups":[{"id":"OG000","title":"Semaglutide 7.2 mg","description":"Participants received escalated dose of semaglutide subcutaneously (s.c.) (0.25, 0.5, 1.0, 1.7, and 2.4 milligrams \\[mg\\]) once weekly for 20 weeks followed by a maintenance dose of semaglutide 7.2 mg s.c. once weekly for 52 weeks."},{"id":"OG001","title":"Semaglutide 2.4 mg","description":"Participants received escalated dose of semaglutide s.c. (0.25, 0.5, 1.0, 1.7 and 2.4 mg) once weekly for 20 weeks followed by a maintenance dose of semaglutide 2.4 mg s.c. once weekly for 52 weeks."},{"id":"OG002","title":"Placebo","description":"Participants received matching placebo to semaglutide s.c. once a week for 72 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"291"},{"groupId":"OG001","value":"97"},{"groupId":"OG002","value":"95"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.9","spread":"10.6"},{"groupId":"OG001","value":"-11.4","spread":"8.9"},{"groupId":"OG002","value":"-4.6","spread":"7.1"}]}]}]},{"type":"SECONDARY","title":"Change in Body Mass Index (BMI)","description":"Change in BMI from baseline (week 0) to end of treatment (week 72) is presented.","populationDescription":"Full analysis set included all randomized participants. Overall number of participants analyzed = Participants with available data for the outcome measure.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"kilograms per meter square (kg/m^2)","timeFrame":"Baseline (week 0), End of treatment (week 72)","groups":[{"id":"OG000","title":"Semaglutide 7.2 mg","description":"Participants received escalated dose of semaglutide subcutaneously (s.c.) (0.25, 0.5, 1.0, 1.7, and 2.4 milligrams \\[mg\\]) once weekly for 20 weeks followed by a maintenance dose of semaglutide 7.2 mg s.c. once weekly for 52 weeks."},{"id":"OG001","title":"Semaglutide 2.4 mg","description":"Participants received escalated dose of semaglutide s.c. (0.25, 0.5, 1.0, 1.7 and 2.4 mg) once weekly for 20 weeks followed by a maintenance dose of semaglutide 2.4 mg s.c. once weekly for 52 weeks."},{"id":"OG002","title":"Placebo","description":"Participants received matching placebo to semaglutide s.c. once a week for 72 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"291"},{"groupId":"OG001","value":"97"},{"groupId":"OG002","value":"95"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.3","spread":"3.8"},{"groupId":"OG001","value":"-4.1","spread":"3.3"},{"groupId":"OG002","value":"-1.6","spread":"2.5"}]}]}]},{"type":"SECONDARY","title":"Change in Systolic Blood Pressure","description":"Change in systolic blood pressure from baseline (week 0) to end of treatment (week 72) is presented.","populationDescription":"Full analysis set included all randomized participants. Overall number of participants analyzed = Participants with available data for the outcome measure.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Millimeters of mercury (mmHg)","timeFrame":"Baseline (week 0), End of treatment (week 72)","groups":[{"id":"OG000","title":"Semaglutide 7.2 mg","description":"Participants received escalated dose of semaglutide subcutaneously (s.c.) (0.25, 0.5, 1.0, 1.7, and 2.4 milligrams \\[mg\\]) once weekly for 20 weeks followed by a maintenance dose of semaglutide 7.2 mg s.c. once weekly for 52 weeks."},{"id":"OG001","title":"Semaglutide 2.4 mg","description":"Participants received escalated dose of semaglutide s.c. (0.25, 0.5, 1.0, 1.7 and 2.4 mg) once weekly for 20 weeks followed by a maintenance dose of semaglutide 2.4 mg s.c. once weekly for 52 weeks."},{"id":"OG002","title":"Placebo","description":"Participants received matching placebo to semaglutide s.c. once a week for 72 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"291"},{"groupId":"OG001","value":"97"},{"groupId":"OG002","value":"95"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-8","spread":"13"},{"groupId":"OG001","value":"-7","spread":"15"},{"groupId":"OG002","value":"-3","spread":"13"}]}]}]},{"type":"SECONDARY","title":"Change in Diastolic Blood Pressure","description":"Change in diastolic blood pressure from baseline (week 0) to end of treatment (week 72) is presented.","populationDescription":"Full analysis set included all randomized participants. Overall number of participants analyzed = Participants with available data for the outcome measure.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mmHg","timeFrame":"Baseline (week 0), End of treatment (week 72)","groups":[{"id":"OG000","title":"Semaglutide 7.2 mg","description":"Participants received escalated dose of semaglutide subcutaneously (s.c.) (0.25, 0.5, 1.0, 1.7, and 2.4 milligrams \\[mg\\]) once weekly for 20 weeks followed by a maintenance dose of semaglutide 7.2 mg s.c. once weekly for 52 weeks."},{"id":"OG001","title":"Semaglutide 2.4 mg","description":"Participants received escalated dose of semaglutide s.c. (0.25, 0.5, 1.0, 1.7 and 2.4 mg) once weekly for 20 weeks followed by a maintenance dose of semaglutide 2.4 mg s.c. once weekly for 52 weeks."},{"id":"OG002","title":"Placebo","description":"Participants received matching placebo to semaglutide s.c. once a week for 72 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"291"},{"groupId":"OG001","value":"97"},{"groupId":"OG002","value":"95"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3","spread":"9"},{"groupId":"OG001","value":"-3","spread":"10"},{"groupId":"OG002","value":"-3","spread":"9"}]}]}]},{"type":"SECONDARY","title":"Change in Total Cholesterol (Millimoles Per Liter [mmol/L]) - Ratio to Baseline","description":"Change in total cholesterol in mmol/L from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.","populationDescription":"Full analysis set included all randomized participants. Overall number of participants analyzed = Participants with available data for the outcome measure.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"Ratio of total cholesterol","timeFrame":"Baseline (week 0), End of treatment (week 72)","groups":[{"id":"OG000","title":"Semaglutide 7.2 mg","description":"Participants received escalated dose of semaglutide subcutaneously (s.c.) (0.25, 0.5, 1.0, 1.7, and 2.4 milligrams \\[mg\\]) once weekly for 20 weeks followed by a maintenance dose of semaglutide 7.2 mg s.c. once weekly for 52 weeks."},{"id":"OG001","title":"Semaglutide 2.4 mg","description":"Participants received escalated dose of semaglutide s.c. (0.25, 0.5, 1.0, 1.7 and 2.4 mg) once weekly for 20 weeks followed by a maintenance dose of semaglutide 2.4 mg s.c. once weekly for 52 weeks."},{"id":"OG002","title":"Placebo","description":"Participants received matching placebo to semaglutide s.c. once a week for 72 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"286"},{"groupId":"OG001","value":"94"},{"groupId":"OG002","value":"94"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.96","spread":"23.0"},{"groupId":"OG001","value":"0.96","spread":"21.1"},{"groupId":"OG002","value":"0.97","spread":"28.3"}]}]}]},{"type":"SECONDARY","title":"Change in Total Cholesterol (Milligrams Per Deciliter [mg/dL]) - Ratio to Baseline","description":"Change in total cholesterol in mg/dL from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.","populationDescription":"Full analysis set included all randomized participants. Overall number of participants analyzed = Participants with available data for the outcome measure.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"Ratio of total cholesterol","timeFrame":"Baseline (week 0), End of treatment (week 72)","groups":[{"id":"OG000","title":"Semaglutide 7.2 mg","description":"Participants received escalated dose of semaglutide subcutaneously (s.c.) (0.25, 0.5, 1.0, 1.7, and 2.4 milligrams \\[mg\\]) once weekly for 20 weeks followed by a maintenance dose of semaglutide 7.2 mg s.c. once weekly for 52 weeks."},{"id":"OG001","title":"Semaglutide 2.4 mg","description":"Participants received escalated dose of semaglutide s.c. (0.25, 0.5, 1.0, 1.7 and 2.4 mg) once weekly for 20 weeks followed by a maintenance dose of semaglutide 2.4 mg s.c. once weekly for 52 weeks."},{"id":"OG002","title":"Placebo","description":"Participants received matching placebo to semaglutide s.c. once a week for 72 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"286"},{"groupId":"OG001","value":"94"},{"groupId":"OG002","value":"94"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.96","spread":"23.0"},{"groupId":"OG001","value":"0.96","spread":"21.1"},{"groupId":"OG002","value":"0.97","spread":"28.3"}]}]}]},{"type":"SECONDARY","title":"Change in High-density Lipoprotein (HDL) Cholesterol (mmol/L) - Ratio to Baseline","description":"Change in HDL cholesterol in mmol/L from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.","populationDescription":"Full analysis set included all randomized participants. Overall number of participants analyzed = Participants with available data for the outcome measure.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"Ratio of HDL cholesterol","timeFrame":"Baseline (week 0), End of treatment (week 72)","groups":[{"id":"OG000","title":"Semaglutide 7.2 mg","description":"Participants received escalated dose of semaglutide subcutaneously (s.c.) (0.25, 0.5, 1.0, 1.7, and 2.4 milligrams \\[mg\\]) once weekly for 20 weeks followed by a maintenance dose of semaglutide 7.2 mg s.c. once weekly for 52 weeks."},{"id":"OG001","title":"Semaglutide 2.4 mg","description":"Participants received escalated dose of semaglutide s.c. (0.25, 0.5, 1.0, 1.7 and 2.4 mg) once weekly for 20 weeks followed by a maintenance dose of semaglutide 2.4 mg s.c. once weekly for 52 weeks."},{"id":"OG002","title":"Placebo","description":"Participants received matching placebo to semaglutide s.c. once a week for 72 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"285"},{"groupId":"OG001","value":"92"},{"groupId":"OG002","value":"91"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.10","spread":"17.8"},{"groupId":"OG001","value":"1.06","spread":"13.5"},{"groupId":"OG002","value":"1.07","spread":"16.1"}]}]}]},{"type":"SECONDARY","title":"Change in HDL Cholesterol (mg/dL) - Ratio to Baseline","description":"Change in HDL cholesterol in mg/dL from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.","populationDescription":"Full analysis set included all randomized participants. Overall number of participants analyzed = Participants with available data for the outcome measure.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"Ratio of HDL cholesterol","timeFrame":"Baseline (week 0), End of treatment (week 72)","groups":[{"id":"OG000","title":"Semaglutide 7.2 mg","description":"Participants received escalated dose of semaglutide subcutaneously (s.c.) (0.25, 0.5, 1.0, 1.7, and 2.4 milligrams \\[mg\\]) once weekly for 20 weeks followed by a maintenance dose of semaglutide 7.2 mg s.c. once weekly for 52 weeks."},{"id":"OG001","title":"Semaglutide 2.4 mg","description":"Participants received escalated dose of semaglutide s.c. (0.25, 0.5, 1.0, 1.7 and 2.4 mg) once weekly for 20 weeks followed by a maintenance dose of semaglutide 2.4 mg s.c. once weekly for 52 weeks."},{"id":"OG002","title":"Placebo","description":"Participants received matching placebo to semaglutide s.c. once a week for 72 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"285"},{"groupId":"OG001","value":"92"},{"groupId":"OG002","value":"91"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.10","spread":"17.8"},{"groupId":"OG001","value":"1.06","spread":"13.5"},{"groupId":"OG002","value":"1.07","spread":"16.1"}]}]}]},{"type":"SECONDARY","title":"Change in Low-density Lipoprotein (LDL) Cholesterol (mmol/L) - Ratio to Baseline","description":"Change in LDL cholesterol in mmol/L from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.","populationDescription":"Full analysis set included all randomized participants. Overall number of participants analyzed = Participants with available data for the outcome measure.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"Ratio of LDL cholesterol","timeFrame":"Baseline (week 0), End of treatment (week 72)","groups":[{"id":"OG000","title":"Semaglutide 7.2 mg","description":"Participants received escalated dose of semaglutide subcutaneously (s.c.) (0.25, 0.5, 1.0, 1.7, and 2.4 milligrams \\[mg\\]) once weekly for 20 weeks followed by a maintenance dose of semaglutide 7.2 mg s.c. once weekly for 52 weeks."},{"id":"OG001","title":"Semaglutide 2.4 mg","description":"Participants received escalated dose of semaglutide s.c. (0.25, 0.5, 1.0, 1.7 and 2.4 mg) once weekly for 20 weeks followed by a maintenance dose of semaglutide 2.4 mg s.c. once weekly for 52 weeks."},{"id":"OG002","title":"Placebo","description":"Participants received matching placebo to semaglutide s.c. once a week for 72 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"285"},{"groupId":"OG001","value":"92"},{"groupId":"OG002","value":"92"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.99","spread":"40.1"},{"groupId":"OG001","value":"0.95","spread":"36.5"},{"groupId":"OG002","value":"0.97","spread":"41.4"}]}]}]},{"type":"SECONDARY","title":"Change in LDL Cholesterol (mg/dL) - Ratio to Baseline","description":"Change in LDL cholesterol in mg/dL from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.","populationDescription":"Full analysis set included all randomized participants. Overall number of participants analyzed = Participants with available data for the outcome measure.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"Ratio of LDL cholesterol","timeFrame":"Baseline (week 0), End of treatment (week 72)","groups":[{"id":"OG000","title":"Semaglutide 7.2 mg","description":"Participants received escalated dose of semaglutide subcutaneously (s.c.) (0.25, 0.5, 1.0, 1.7, and 2.4 milligrams \\[mg\\]) once weekly for 20 weeks followed by a maintenance dose of semaglutide 7.2 mg s.c. once weekly for 52 weeks."},{"id":"OG001","title":"Semaglutide 2.4 mg","description":"Participants received escalated dose of semaglutide s.c. (0.25, 0.5, 1.0, 1.7 and 2.4 mg) once weekly for 20 weeks followed by a maintenance dose of semaglutide 2.4 mg s.c. once weekly for 52 weeks."},{"id":"OG002","title":"Placebo","description":"Participants received matching placebo to semaglutide s.c. once a week for 72 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"285"},{"groupId":"OG001","value":"92"},{"groupId":"OG002","value":"92"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.99","spread":"40.1"},{"groupId":"OG001","value":"0.95","spread":"36.5"},{"groupId":"OG002","value":"0.97","spread":"41.4"}]}]}]},{"type":"SECONDARY","title":"Change in Very-low-density Lipoprotein (VLDL) Cholesterol (mmol/L) - Ratio to Baseline","description":"Change in VLDL cholesterol in mmol/L from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.","populationDescription":"Full analysis set included all randomized participants. Overall number of participants analyzed = Participants with available data for the outcome measure.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"Ratio of VLDL cholesterol","timeFrame":"Baseline (week 0), End of treatment (week 72)","groups":[{"id":"OG000","title":"Semaglutide 7.2 mg","description":"Participants received escalated dose of semaglutide subcutaneously (s.c.) (0.25, 0.5, 1.0, 1.7, and 2.4 milligrams \\[mg\\]) once weekly for 20 weeks followed by a maintenance dose of semaglutide 7.2 mg s.c. once weekly for 52 weeks."},{"id":"OG001","title":"Semaglutide 2.4 mg","description":"Participants received escalated dose of semaglutide s.c. (0.25, 0.5, 1.0, 1.7 and 2.4 mg) once weekly for 20 weeks followed by a maintenance dose of semaglutide 2.4 mg s.c. once weekly for 52 weeks."},{"id":"OG002","title":"Placebo","description":"Participants received matching placebo to semaglutide s.c. once a week for 72 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"286"},{"groupId":"OG001","value":"94"},{"groupId":"OG002","value":"93"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.72","spread":"42.5"},{"groupId":"OG001","value":"0.81","spread":"40.4"},{"groupId":"OG002","value":"0.90","spread":"47.8"}]}]}]},{"type":"SECONDARY","title":"Change in VLDL Cholesterol (mg/dL) - Ratio to Baseline","description":"Change in VLDL cholesterol in mg/dL from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.","populationDescription":"Full analysis set included all randomized participants. Overall number of participants analyzed = Participants with available data for the outcome measure.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"Ratio of VLDL cholesterol","timeFrame":"Baseline (week 0), End of treatment (week 72)","groups":[{"id":"OG000","title":"Semaglutide 7.2 mg","description":"Participants received escalated dose of semaglutide subcutaneously (s.c.) (0.25, 0.5, 1.0, 1.7, and 2.4 milligrams \\[mg\\]) once weekly for 20 weeks followed by a maintenance dose of semaglutide 7.2 mg s.c. once weekly for 52 weeks."},{"id":"OG001","title":"Semaglutide 2.4 mg","description":"Participants received escalated dose of semaglutide s.c. (0.25, 0.5, 1.0, 1.7 and 2.4 mg) once weekly for 20 weeks followed by a maintenance dose of semaglutide 2.4 mg s.c. once weekly for 52 weeks."},{"id":"OG002","title":"Placebo","description":"Participants received matching placebo to semaglutide s.c. once a week for 72 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"286"},{"groupId":"OG001","value":"94"},{"groupId":"OG002","value":"93"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.72","spread":"42.5"},{"groupId":"OG001","value":"0.81","spread":"40.4"},{"groupId":"OG002","value":"0.90","spread":"47.8"}]}]}]},{"type":"SECONDARY","title":"Change in Triglycerides (mmol/L) - Ratio to Baseline","description":"Change in triglycerides in mmol/L from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.","populationDescription":"Full analysis set included all randomized participants. Overall number of participants analyzed = Participants with available data for the outcome measure.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"Ratio of triglycerides","timeFrame":"Baseline (week 0), End of treatment (week 72)","groups":[{"id":"OG000","title":"Semaglutide 7.2 mg","description":"Participants received escalated dose of semaglutide subcutaneously (s.c.) (0.25, 0.5, 1.0, 1.7, and 2.4 milligrams \\[mg\\]) once weekly for 20 weeks followed by a maintenance dose of semaglutide 7.2 mg s.c. once weekly for 52 weeks."},{"id":"OG001","title":"Semaglutide 2.4 mg","description":"Participants received escalated dose of semaglutide s.c. (0.25, 0.5, 1.0, 1.7 and 2.4 mg) once weekly for 20 weeks followed by a maintenance dose of semaglutide 2.4 mg s.c. once weekly for 52 weeks."},{"id":"OG002","title":"Placebo","description":"Participants received matching placebo to semaglutide s.c. once a week for 72 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"286"},{"groupId":"OG001","value":"94"},{"groupId":"OG002","value":"94"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.71","spread":"46.2"},{"groupId":"OG001","value":"0.80","spread":"42.2"},{"groupId":"OG002","value":"0.87","spread":"54.4"}]}]}]},{"type":"SECONDARY","title":"Change in Triglycerides (mg/dL) - Ratio to Baseline","description":"Change in triglycerides in mg/dL from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.","populationDescription":"Full analysis set included all randomized participants. Overall number of participants analyzed = Participants with available data for the outcome measure.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"Ratio of triglycerides","timeFrame":"Baseline (week 0), End of treatment (week 72)","groups":[{"id":"OG000","title":"Semaglutide 7.2 mg","description":"Participants received escalated dose of semaglutide subcutaneously (s.c.) (0.25, 0.5, 1.0, 1.7, and 2.4 milligrams \\[mg\\]) once weekly for 20 weeks followed by a maintenance dose of semaglutide 7.2 mg s.c. once weekly for 52 weeks."},{"id":"OG001","title":"Semaglutide 2.4 mg","description":"Participants received escalated dose of semaglutide s.c. (0.25, 0.5, 1.0, 1.7 and 2.4 mg) once weekly for 20 weeks followed by a maintenance dose of semaglutide 2.4 mg s.c. once weekly for 52 weeks."},{"id":"OG002","title":"Placebo","description":"Participants received matching placebo to semaglutide s.c. once a week for 72 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"286"},{"groupId":"OG001","value":"94"},{"groupId":"OG002","value":"94"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.71","spread":"46.2"},{"groupId":"OG001","value":"0.80","spread":"42.2"},{"groupId":"OG002","value":"0.87","spread":"54.4"}]}]}]},{"type":"SECONDARY","title":"Change in Free Fatty Acids (mmol/L) - Ratio to Baseline","description":"Change in free fatty acids in mmol/L from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.","populationDescription":"Full analysis set included all randomized participants. Overall number of participants analyzed = Participants with available data for the outcome measure.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"Ratio of free fatty acids","timeFrame":"Baseline (week 0), End of treatment (week 72)","groups":[{"id":"OG000","title":"Semaglutide 7.2 mg","description":"Participants received escalated dose of semaglutide subcutaneously (s.c.) (0.25, 0.5, 1.0, 1.7, and 2.4 milligrams \\[mg\\]) once weekly for 20 weeks followed by a maintenance dose of semaglutide 7.2 mg s.c. once weekly for 52 weeks."},{"id":"OG001","title":"Semaglutide 2.4 mg","description":"Participants received escalated dose of semaglutide s.c. (0.25, 0.5, 1.0, 1.7 and 2.4 mg) once weekly for 20 weeks followed by a maintenance dose of semaglutide 2.4 mg s.c. once weekly for 52 weeks."},{"id":"OG002","title":"Placebo","description":"Participants received matching placebo to semaglutide s.c. once a week for 72 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"284"},{"groupId":"OG001","value":"93"},{"groupId":"OG002","value":"92"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.74","spread":"69.8"},{"groupId":"OG001","value":"0.81","spread":"70.6"},{"groupId":"OG002","value":"0.98","spread":"65.8"}]}]}]},{"type":"SECONDARY","title":"Change in Free Fatty Acids (mg/dL) - Ratio to Baseline","description":"Change in free fatty acids in mg/dL from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.","populationDescription":"Full analysis set included all randomized participants. Overall number of participants analyzed = Participants with available data for the outcome measure.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"Ratio of free fatty acids","timeFrame":"Baseline (week 0), End of treatment (week 72)","groups":[{"id":"OG000","title":"Semaglutide 7.2 mg","description":"Participants received escalated dose of semaglutide subcutaneously (s.c.) (0.25, 0.5, 1.0, 1.7, and 2.4 milligrams \\[mg\\]) once weekly for 20 weeks followed by a maintenance dose of semaglutide 7.2 mg s.c. once weekly for 52 weeks."},{"id":"OG001","title":"Semaglutide 2.4 mg","description":"Participants received escalated dose of semaglutide s.c. (0.25, 0.5, 1.0, 1.7 and 2.4 mg) once weekly for 20 weeks followed by a maintenance dose of semaglutide 2.4 mg s.c. once weekly for 52 weeks."},{"id":"OG002","title":"Placebo","description":"Participants received matching placebo to semaglutide s.c. once a week for 72 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"284"},{"groupId":"OG001","value":"93"},{"groupId":"OG002","value":"92"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.74","spread":"69.8"},{"groupId":"OG001","value":"0.81","spread":"70.6"},{"groupId":"OG002","value":"0.98","spread":"65.8"}]}]}]},{"type":"SECONDARY","title":"Change in High-sensitivity C-reactive Protein (hsCRP) - Ratio to Baseline","description":"Change in hsCRP in mg/L from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.","populationDescription":"Full analysis set included all randomized participants. Overall number of participants analyzed = Participants with available data for the outcome measure.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"Ratio of hsCRP","timeFrame":"Baseline (week 0), End of treatment (week 72)","groups":[{"id":"OG000","title":"Semaglutide 7.2 mg","description":"Participants received escalated dose of semaglutide subcutaneously (s.c.) (0.25, 0.5, 1.0, 1.7, and 2.4 milligrams \\[mg\\]) once weekly for 20 weeks followed by a maintenance dose of semaglutide 7.2 mg s.c. once weekly for 52 weeks."},{"id":"OG001","title":"Semaglutide 2.4 mg","description":"Participants received escalated dose of semaglutide s.c. (0.25, 0.5, 1.0, 1.7 and 2.4 mg) once weekly for 20 weeks followed by a maintenance dose of semaglutide 2.4 mg s.c. once weekly for 52 weeks."},{"id":"OG002","title":"Placebo","description":"Participants received matching placebo to semaglutide s.c. once a week for 72 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"286"},{"groupId":"OG001","value":"95"},{"groupId":"OG002","value":"95"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.47","spread":"166.7"},{"groupId":"OG001","value":"0.48","spread":"121.1"},{"groupId":"OG002","value":"0.82","spread":"96.0"}]}]}]},{"type":"SECONDARY","title":"Change in Fasting Plasma Glucose","description":"Change in fasting plasma glucose from baseline (week 0) to end of treatment (week 72) is presented.","populationDescription":"Full analysis set included all randomized participants. Overall number of participants analyzed = Participants with available data for the outcome measure.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mg/dL","timeFrame":"Baseline (week 0), End of treatment (week 72)","groups":[{"id":"OG000","title":"Semaglutide 7.2 mg","description":"Participants received escalated dose of semaglutide subcutaneously (s.c.) (0.25, 0.5, 1.0, 1.7, and 2.4 milligrams \\[mg\\]) once weekly for 20 weeks followed by a maintenance dose of semaglutide 7.2 mg s.c. once weekly for 52 weeks."},{"id":"OG001","title":"Semaglutide 2.4 mg","description":"Participants received escalated dose of semaglutide s.c. (0.25, 0.5, 1.0, 1.7 and 2.4 mg) once weekly for 20 weeks followed by a maintenance dose of semaglutide 2.4 mg s.c. once weekly for 52 weeks."},{"id":"OG002","title":"Placebo","description":"Participants received matching placebo to semaglutide s.c. once a week for 72 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"281"},{"groupId":"OG001","value":"93"},{"groupId":"OG002","value":"93"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-59.6","spread":"53.1"},{"groupId":"OG001","value":"-58.4","spread":"46.3"},{"groupId":"OG002","value":"-20.2","spread":"68.7"}]}]}]},{"type":"SECONDARY","title":"Change in Fasting Serum Insulin (Picomoles Per Liter [Pmol/L]) - Ratio to Baseline","description":"Change in fasting serum insulin in pmol/L from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.","populationDescription":"Full analysis set included all randomized participants. Overall number of participants analyzed = Participants with available data for the outcome measure.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"Ratio of fasting serum insulin","timeFrame":"Baseline (week 0), End of treatment (week 72)","groups":[{"id":"OG000","title":"Semaglutide 7.2 mg","description":"Participants received escalated dose of semaglutide subcutaneously (s.c.) (0.25, 0.5, 1.0, 1.7, and 2.4 milligrams \\[mg\\]) once weekly for 20 weeks followed by a maintenance dose of semaglutide 7.2 mg s.c. once weekly for 52 weeks."},{"id":"OG001","title":"Semaglutide 2.4 mg","description":"Participants received escalated dose of semaglutide s.c. (0.25, 0.5, 1.0, 1.7 and 2.4 mg) once weekly for 20 weeks followed by a maintenance dose of semaglutide 2.4 mg s.c. once weekly for 52 weeks."},{"id":"OG002","title":"Placebo","description":"Participants received matching placebo to semaglutide s.c. once a week for 72 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"281"},{"groupId":"OG001","value":"92"},{"groupId":"OG002","value":"91"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.77","spread":"66.5"},{"groupId":"OG001","value":"0.90","spread":"70.6"},{"groupId":"OG002","value":"0.87","spread":"71.4"}]}]}]},{"type":"SECONDARY","title":"Change in Fasting Serum Insulin (Milliinternational Units Per Milliliter [mIU/mL]) - Ratio to Baseline","description":"Change in fasting serum insulin in mIU/ml from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.","populationDescription":"Full analysis set included all randomized participants. Overall number of participants analyzed = Participants with available data for the outcome measure.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"Ratio of fasting serum insulin","timeFrame":"Baseline (week 0), End of treatment (week 72)","groups":[{"id":"OG000","title":"Semaglutide 7.2 mg","description":"Participants received escalated dose of semaglutide subcutaneously (s.c.) (0.25, 0.5, 1.0, 1.7, and 2.4 milligrams \\[mg\\]) once weekly for 20 weeks followed by a maintenance dose of semaglutide 7.2 mg s.c. once weekly for 52 weeks."},{"id":"OG001","title":"Semaglutide 2.4 mg","description":"Participants received escalated dose of semaglutide s.c. (0.25, 0.5, 1.0, 1.7 and 2.4 mg) once weekly for 20 weeks followed by a maintenance dose of semaglutide 2.4 mg s.c. once weekly for 52 weeks."},{"id":"OG002","title":"Placebo","description":"Participants received matching placebo to semaglutide s.c. once a week for 72 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"281"},{"groupId":"OG001","value":"92"},{"groupId":"OG002","value":"91"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.77","spread":"66.5"},{"groupId":"OG001","value":"0.90","spread":"70.6"},{"groupId":"OG002","value":"0.87","spread":"71.4"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With HbA1c Less Than 7.0 % (53 Millimoles Per Mole [mmol/Mol])","description":"Number of participants with HbA1c less than 7.0 % (53 mmol/mol) at week 72 is presented.","populationDescription":"Full analysis set included all randomized participants. Overall number of participants analyzed = Participants with available data for the outcome measure.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"At week 72","groups":[{"id":"OG000","title":"Semaglutide 7.2 mg","description":"Participants received escalated dose of semaglutide subcutaneously (s.c.) (0.25, 0.5, 1.0, 1.7, and 2.4 milligrams \\[mg\\]) once weekly for 20 weeks followed by a maintenance dose of semaglutide 7.2 mg s.c. once weekly for 52 weeks."},{"id":"OG001","title":"Semaglutide 2.4 mg","description":"Participants received escalated dose of semaglutide s.c. (0.25, 0.5, 1.0, 1.7 and 2.4 mg) once weekly for 20 weeks followed by a maintenance dose of semaglutide 2.4 mg s.c. once weekly for 52 weeks."},{"id":"OG002","title":"Placebo","description":"Participants received matching placebo to semaglutide s.c. once a week for 72 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"288"},{"groupId":"OG001","value":"96"},{"groupId":"OG002","value":"94"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"235"},{"groupId":"OG001","value":"75"},{"groupId":"OG002","value":"27"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With HbA1c Less Than or Equal to 6.5% (48 mmol/Mol)","description":"Number of participants with HbA1c less than or equal to 6.5% (48 mmol/mol) at week 72 is presented.","populationDescription":"Full analysis set included all randomized participants. Overall number of participants analyzed = Participants with available data for the outcome measure.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"At week 72","groups":[{"id":"OG000","title":"Semaglutide 7.2 mg","description":"Participants received escalated dose of semaglutide subcutaneously (s.c.) (0.25, 0.5, 1.0, 1.7, and 2.4 milligrams \\[mg\\]) once weekly for 20 weeks followed by a maintenance dose of semaglutide 7.2 mg s.c. once weekly for 52 weeks."},{"id":"OG001","title":"Semaglutide 2.4 mg","description":"Participants received escalated dose of semaglutide s.c. (0.25, 0.5, 1.0, 1.7 and 2.4 mg) once weekly for 20 weeks followed by a maintenance dose of semaglutide 2.4 mg s.c. once weekly for 52 weeks."},{"id":"OG002","title":"Placebo","description":"Participants received matching placebo to semaglutide s.c. once a week for 72 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"288"},{"groupId":"OG001","value":"96"},{"groupId":"OG002","value":"94"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"209"},{"groupId":"OG001","value":"64"},{"groupId":"OG002","value":"15"}]}]}]},{"type":"SECONDARY","title":"Semaglutide 7.2 mg Versus Placebo: Number of Adverse Events (AEs)","description":"Number of AEs is reported. An AE is any untoward medical occurrence in a clinical study participant that is temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to the IMP.","populationDescription":"Safety analysis set included all participants who were exposed to at least one dose of randomised IMP.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Events","timeFrame":"At week 81","groups":[{"id":"OG000","title":"Semaglutide 7.2 mg","description":"Participants received escalated dose of semaglutide subcutaneously (s.c.) (0.25, 0.5, 1.0, 1.7, and 2.4 milligrams \\[mg\\]) once weekly for 20 weeks followed by a maintenance dose of semaglutide 7.2 mg s.c. once weekly for 52 weeks."},{"id":"OG001","title":"Placebo","description":"Participants received matching placebo to semaglutide s.c. once a week for 72 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"307"},{"groupId":"OG001","value":"102"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1581"},{"groupId":"OG001","value":"253"}]}]}]},{"type":"SECONDARY","title":"Semaglutide 7.2 mg Versus Placebo: Number of Serious Adverse Events (SAEs)","description":"Number of SAEs is reported. A SAE is any untoward medical occurrence that fulfils at least one of the following criteria: results in death, is life threatening, requires inpatient hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or important medical event.","populationDescription":"Safety analysis set included all participants who were exposed to at least one dose of randomised IMP.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Events","timeFrame":"At week 81","groups":[{"id":"OG000","title":"Semaglutide 7.2 mg","description":"Participants received escalated dose of semaglutide subcutaneously (s.c.) (0.25, 0.5, 1.0, 1.7, and 2.4 milligrams \\[mg\\]) once weekly for 20 weeks followed by a maintenance dose of semaglutide 7.2 mg s.c. once weekly for 52 weeks."},{"id":"OG001","title":"Placebo","description":"Participants received matching placebo to semaglutide s.c. once a week for 72 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"307"},{"groupId":"OG001","value":"102"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39"},{"groupId":"OG001","value":"21"}]}]}]},{"type":"SECONDARY","title":"Change in Pulse","description":"Change in pulse from baseline (week 0) to end of treatment (week 72) is presented.","populationDescription":"Safety analysis set included all participants who were exposed to at least one dose of randomised IMP. Overall number of participants analyzed = Participants with available data for the outcome measure.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Beats per minute (bpm)","timeFrame":"Baseline (week 0), End of treatment (week 72)","groups":[{"id":"OG000","title":"Semaglutide 7.2 mg","description":"Participants received escalated dose of semaglutide subcutaneously (s.c.) (0.25, 0.5, 1.0, 1.7, and 2.4 milligrams \\[mg\\]) once weekly for 20 weeks followed by a maintenance dose of semaglutide 7.2 mg s.c. once weekly for 52 weeks."},{"id":"OG001","title":"Semaglutide 2.4 mg","description":"Participants received escalated dose of semaglutide s.c. (0.25, 0.5, 1.0, 1.7 and 2.4 mg) once weekly for 20 weeks followed by a maintenance dose of semaglutide 2.4 mg s.c. once weekly for 52 weeks."},{"id":"OG002","title":"Placebo","description":"Participants received matching placebo to semaglutide s.c. once a week for 72 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"271"},{"groupId":"OG001","value":"92"},{"groupId":"OG002","value":"84"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":"10"},{"groupId":"OG001","value":"2","spread":"10"},{"groupId":"OG002","value":"-4","spread":"9"}]}]}]},{"type":"SECONDARY","title":"Semaglutide 7.2 mg Versus Placebo: Number of Treatment Emergent Severe or Blood Glucose Confirmed Symptomatic Hypoglycaemic Episodes","description":"Number of treatment emergent severe or blood glucose confirmed symptomatic hypoglycaemic episodes is presented.","populationDescription":"Safety analysis set included all participants who were exposed to at least one dose of randomised IMP.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Episodes","timeFrame":"At week 81","groups":[{"id":"OG000","title":"Semaglutide 7.2 mg","description":"Participants received escalated dose of semaglutide subcutaneously (s.c.) (0.25, 0.5, 1.0, 1.7, and 2.4 milligrams \\[mg\\]) once weekly for 20 weeks followed by a maintenance dose of semaglutide 7.2 mg s.c. once weekly for 52 weeks."},{"id":"OG001","title":"Placebo","description":"Participants received matching placebo to semaglutide s.c. once a week for 72 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"307"},{"groupId":"OG001","value":"102"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]}]},{"type":"SECONDARY","title":"Semaglutide 7.2 mg Versus Semaglutide 2.4 mg: Number of AEs","description":"Number of AEs is reported. An AE is any untoward medical occurrence in a clinical study participant that is temporally associated with the use of IMP, whether or not considered related to the IMP.","populationDescription":"Safety analysis set included all participants who were exposed to at least one dose of randomised IMP.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Events","timeFrame":"At week 81","groups":[{"id":"OG000","title":"Semaglutide 7.2 mg","description":"Participants received escalated dose of semaglutide subcutaneously (s.c.) (0.25, 0.5, 1.0, 1.7, and 2.4 milligrams \\[mg\\]) once weekly for 20 weeks followed by a maintenance dose of semaglutide 7.2 mg s.c. once weekly for 52 weeks."},{"id":"OG001","title":"Semaglutide 2.4 mg","description":"Participants received escalated dose of semaglutide s.c. (0.25, 0.5, 1.0, 1.7 and 2.4 mg) once weekly for 20 weeks followed by a maintenance dose of semaglutide 2.4 mg s.c. once weekly for 52 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"307"},{"groupId":"OG001","value":"103"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1581"},{"groupId":"OG001","value":"508"}]}]}]},{"type":"SECONDARY","title":"Semaglutide 7.2 mg Versus Semaglutide 2.4 mg: Number of SAEs","description":"Number of SAEs is reported. A SAE is any untoward medical occurrence that fulfils at least one of the following criteria: results in death, is life threatening, requires inpatient hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or important medical event.","populationDescription":"Safety analysis set included all participants who were exposed to at least one dose of randomised IMP.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Events","timeFrame":"At week 81","groups":[{"id":"OG000","title":"Semaglutide 7.2 mg","description":"Participants received escalated dose of semaglutide subcutaneously (s.c.) (0.25, 0.5, 1.0, 1.7, and 2.4 milligrams \\[mg\\]) once weekly for 20 weeks followed by a maintenance dose of semaglutide 7.2 mg s.c. once weekly for 52 weeks."},{"id":"OG001","title":"Semaglutide 2.4 mg","description":"Participants received escalated dose of semaglutide s.c. (0.25, 0.5, 1.0, 1.7 and 2.4 mg) once weekly for 20 weeks followed by a maintenance dose of semaglutide 2.4 mg s.c. once weekly for 52 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"307"},{"groupId":"OG001","value":"103"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39"},{"groupId":"OG001","value":"35"}]}]}]},{"type":"SECONDARY","title":"Semaglutide 7.2 mg Versus Semaglutide 2.4 mg: Number of Treatment Emergent Severe or Blood Glucose Confirmed Symptomatic Hypoglycaemic Episodes","description":"Number of treatment emergent severe or blood glucose confirmed symptomatic hypoglycaemic episodes is presented.","populationDescription":"Safety analysis set included all participants who were exposed to at least one dose of randomised IMP.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Episodes","timeFrame":"At week 81","groups":[{"id":"OG000","title":"Semaglutide 7.2 mg","description":"Participants received escalated dose of semaglutide subcutaneously (s.c.) (0.25, 0.5, 1.0, 1.7, and 2.4 milligrams \\[mg\\]) once weekly for 20 weeks followed by a maintenance dose of semaglutide 7.2 mg s.c. once weekly for 52 weeks."},{"id":"OG001","title":"Semaglutide 2.4 mg","description":"Participants received escalated dose of semaglutide s.c. (0.25, 0.5, 1.0, 1.7 and 2.4 mg) once weekly for 20 weeks followed by a maintenance dose of semaglutide 2.4 mg s.c. once weekly for 52 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"307"},{"groupId":"OG001","value":"103"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"From week 0 to week 81","description":"Safety analysis set included all participants who were exposed to at least one dose of randomised IMP. All presented AEs are treatment emergent AEs (TEAEs). A TEAE is defined as an adverse event which occured during the in-trial period.","eventGroups":[{"id":"EG000","title":"Semaglutide 7.2 mg","description":"Participants received escalated dose of semaglutide subcutaneously (s.c.) (0.25, 0.5, 1.0, 1.7, and 2.4 milligrams \\[mg\\]) once weekly for 20 weeks followed by a maintenance dose of semaglutide 7.2 mg s.c. once weekly for 52 weeks.","deathsNumAffected":4,"deathsNumAtRisk":307,"seriousNumAffected":30,"seriousNumAtRisk":307,"otherNumAffected":187,"otherNumAtRisk":307},{"id":"EG001","title":"Semaglutide 2.4 mg","description":"Participants received escalated dose of semaglutide s.c. (0.25, 0.5, 1.0, 1.7 and 2.4 mg) once weekly for 20 weeks followed by a maintenance dose of semaglutide 2.4 mg s.c. once weekly for 52 weeks.","deathsNumAffected":1,"deathsNumAtRisk":103,"seriousNumAffected":11,"seriousNumAtRisk":103,"otherNumAffected":64,"otherNumAtRisk":103},{"id":"EG002","title":"Placebo","description":"Participants received matching placebo to semaglutide s.c. once a week for 72 weeks.","deathsNumAffected":1,"deathsNumAtRisk":102,"seriousNumAffected":10,"seriousNumAtRisk":102,"otherNumAffected":40,"otherNumAtRisk":102}],"seriousEvents":[{"term":"Acute kidney injury","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":103},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Acute left ventricular failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":103},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Acute myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":307},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":103},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Acute respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":307},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":103},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Adenocarcinoma of colon","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":103},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":103},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Angina unstable","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":307},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":103},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Anginal equivalent","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":307},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":103},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Ankylosing spondylitis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":307},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":103},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Aortic aneurysm","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":103},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Arrhythmia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":307},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":103},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":307},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":103},{"groupId":"EG002","numEvents":7,"numAffected":3,"numAtRisk":102}]},{"term":"Azotaemia","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":103},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Bell's palsy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":103},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Breast cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":307},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":103},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Cardiac arrest","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":103},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Cardiac failure acute","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":103},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Cardiac failure congestive","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":307},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":103},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Cardiomyopathy","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":103},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Carotid artery stenosis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":103},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Cataract","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":307},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":103},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Cerebral haemorrhage","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":103},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Cerebral small vessel ischaemic disease","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":103},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":103},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Cholelithiasis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":103},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Coronary artery disease","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":307},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":103},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Death","organSystem":"General disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":307},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":103},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Disseminated intravascular coagulation","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":103},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Erysipelas","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":307},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":103},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Gangrene","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":307},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":103},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Hepatic mass","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":103},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Hyperammonaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":103},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Hyperkalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":103},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Hyperphosphataemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":103},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Interstitial lung disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":307},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":103},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Intervertebral disc injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":307},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":103},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Intervertebral disc protrusion","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":103},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Invasive ductal breast carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":307},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":103},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Iridocyclitis","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":307},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":103},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Ischaemic stroke","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":307},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":103},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Joint abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":307},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":103},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Liver injury","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":103},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Localised infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":103},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Lung adenocarcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":307},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":103},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Lung neoplasm malignant","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":103},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Macular oedema","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":103},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Metabolic acidosis","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":103},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":103},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Nasal septum deviation","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":307},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":103},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Nephrolithiasis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":103},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Optic neuritis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":307},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":103},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Orthostatic hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":103},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Osteolysis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":103},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Osteomyelitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":307},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":103},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Ovarian adenoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":307},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":103},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Ovarian cancer stage III","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":307},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":103},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Peripheral arterial occlusive disease","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":307},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":103},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":103},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Postmenopausal haemorrhage","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":307},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":103},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Prostate cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":307},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":103},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Pulmonary fibrosis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":307},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":103},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Pulmonary oedema","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":103},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Renal colic","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":103},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":103},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Squamous cell carcinoma of the tongue","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":307},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":103},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Subcutaneous abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":307},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":103},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Toxic encephalopathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":103},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Upper gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":307},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":103},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":103},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Cerebrovascular accident","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":103},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Encephalopathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":103},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Facial paralysis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":103},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Ileus paralytic","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":307},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":103},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Nodal rhythm","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":307},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":103},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Paraesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":103},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Umbilical hernia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":307},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":103},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Varicose vein","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":307},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":103},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":102}]}],"otherEvents":[{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":19,"numAffected":16,"numAtRisk":307},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":103},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":102}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":21,"numAffected":16,"numAtRisk":307},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":103},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":102}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":18,"numAffected":17,"numAtRisk":307},{"groupId":"EG001","numEvents":8,"numAffected":7,"numAtRisk":103},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":102}]},{"term":"COVID-19","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":22,"numAffected":22,"numAtRisk":307},{"groupId":"EG001","numEvents":6,"numAffected":5,"numAtRisk":103},{"groupId":"EG002","numEvents":7,"numAffected":7,"numAtRisk":102}]},{"term":"Cataract","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":9,"numAtRisk":307},{"groupId":"EG001","numEvents":7,"numAffected":6,"numAtRisk":103},{"groupId":"EG002","numEvents":6,"numAffected":4,"numAtRisk":102}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":55,"numAffected":45,"numAtRisk":307},{"groupId":"EG001","numEvents":21,"numAffected":19,"numAtRisk":103},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":102}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":25,"numAffected":21,"numAtRisk":307},{"groupId":"EG001","numEvents":9,"numAffected":8,"numAtRisk":103},{"groupId":"EG002","numEvents":6,"numAffected":5,"numAtRisk":102}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":98,"numAffected":56,"numAtRisk":307},{"groupId":"EG001","numEvents":35,"numAffected":21,"numAtRisk":103},{"groupId":"EG002","numEvents":13,"numAffected":9,"numAtRisk":102}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":36,"numAffected":25,"numAtRisk":307},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":103},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":102}]},{"term":"Eructation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":11,"numAtRisk":307},{"groupId":"EG001","numEvents":9,"numAffected":8,"numAtRisk":103},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":34,"numAffected":21,"numAtRisk":307},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":103},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":102}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":42,"numAffected":22,"numAtRisk":307},{"groupId":"EG001","numEvents":11,"numAffected":8,"numAtRisk":103},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":102}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":9,"numAtRisk":307},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":103},{"groupId":"EG002","numEvents":9,"numAffected":8,"numAtRisk":102}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":206,"numAffected":89,"numAtRisk":307},{"groupId":"EG001","numEvents":57,"numAffected":29,"numAtRisk":103},{"groupId":"EG002","numEvents":18,"numAffected":12,"numAtRisk":102}]},{"term":"Sensitive skin","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":24,"numAffected":18,"numAtRisk":307},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":103},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":21,"numAffected":17,"numAtRisk":307},{"groupId":"EG001","numEvents":9,"numAffected":9,"numAtRisk":103},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":102}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":78,"numAffected":51,"numAtRisk":307},{"groupId":"EG001","numEvents":39,"numAffected":14,"numAtRisk":103},{"groupId":"EG002","numEvents":4,"numAffected":3,"numAtRisk":102}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property."},"pointOfContact":{"title":"Clinical Reporting Office (2834)","organization":"Novo Nordisk A/S","email":"clinicaltrials@novonordisk.com","phone":"(+1) 866-867-7178"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2023-06-22","uploadDate":"2026-03-26T02:25","filename":"Prot_000.pdf","size":19204733},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2025-01-07","uploadDate":"2026-03-26T02:25","filename":"SAP_001.pdf","size":629748}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-10-09","submissionTracking":{"firstMcpInfo":{"postDateStruct":{"date":"2026-04-15","type":"ACTUAL"}}}},"conditionBrowseModule":{"meshes":[{"id":"D009765","term":"Obesity"},{"id":"D003924","term":"Diabetes Mellitus, Type 2"}],"ancestors":[{"id":"D050177","term":"Overweight"},{"id":"D044343","term":"Overnutrition"},{"id":"D009748","term":"Nutrition Disorders"},{"id":"D009750","term":"Nutritional and Metabolic Diseases"},{"id":"D001835","term":"Body Weight"},{"id":"D012816","term":"Signs and Symptoms"},{"id":"D013568","term":"Pathological Conditions, Signs and Symptoms"},{"id":"D003920","term":"Diabetes Mellitus"},{"id":"D044882","term":"Glucose Metabolism Disorders"},{"id":"D008659","term":"Metabolic Diseases"},{"id":"D004700","term":"Endocrine System Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C000591245","term":"semaglutide"}]}},"hasResults":true}